- A treatment for cats with a COVID-related infection may help advance Long COVID research. In a small study in Stem Cells Translation Medicine, researchers treated 10 cats who got feline infectious peritonitis (FIP), a feline coronavirus infection that triggers immune dysfunction, and found that those who received a combination of the antiviral drug GS-441524 and mesenchymal stem/stromal cell (MSC) therapy had “enhanced immune recovery.” The authors concluded that this study shows “the power of translational research to inform therapies for persistent and inflammatory conditions like [Long COVID].” Read more about the study in GEN.
- The supplement Oxaloacetate may help reduce fatigue for Long COVID, but it “did not reach statistical significance,” according to a new study from the Bateman Horne Center. Published in Frontiers Neuroscience, the randomized, double-blind clinical trial included 69 participants with Long COVID who took the drug or a placebo for 42 days. But two separate symptom questionnaires used to measure outcomes had conflicting results. The authors concluded that the findings support further investigation of the supplement with longer duration trials and more responsive outcome measures.
- A new prospective cohort study in JAMA Oncology of 1,572 participants with cancer found that COVID-19 had a “significant impact” on these patients, including hospitalization, treatment disruptions, and death. The authors wrote that the data highlight the importance of “continued surveillance and prevention strategies in populations at highest risk for complications.”
